Should Investors Worry About Moderna's European Vaccine Delivery Delay?

Moderna's (NASDAQ: MRNA) second quarter might not be as strong as expected. The company announced today that it has reached an agreement with the European Commission to revise the contractual delivery schedules for shipping its COVID-19 vaccine boosters. Booster doses scheduled for delivery in Q2 will now likely be pushed back to the second half of 2022 or even into early 2023.

The vaccine stock was down 6.5% as of 10:45 a.m. ET on Thursday on the news. Should investors worry about Moderna's European vaccine delivery delay?

Image source: Getty Images.

Continue reading

Source Fool.com